2型神经纤维瘤病的人群特征与进行性残疾
本研究基于2009至2013年日本全国NF2登记库,回顾性分析807例2型神经纤维瘤病(NF2)患者的临床特征,并对587例有纵向残疾数据的患者行多因素logistic回归,识别残疾显著进展的危险因素。结果显示该人群临床特征异质,6.1%患者残疾评分进展≥5分;起病年龄<25岁、家族史阳性、治疗史阳性及特定神经功能缺损为独立危险因素。
要点
- 日本NF2人群临床特征异质,中位起病年龄24岁,25分制初始严重度评分中位4分。
- 6.1%患者研究期间残疾评分进展≥5分。
- 起病年龄<25岁、家族史阳性、治疗史阳性及听力丧失、面瘫、失明、偏瘫为进展独立危险因素。
核心结论
- 日本NF2人群临床特征异质;进行性残疾的危险因素包括起病年龄较轻、家族史阳性、治疗史阳性及特定神经功能缺损。
研究设计与样本
- 2009至2013年日本全国NF2登记库的回顾性队列研究,纳入807例确诊NF2患者,其中587例有纵向残疾数据并接受多因素logistic回归分析。
- 采用涵盖多种神经功能缺损的25分制综合评分评估神经残疾总体严重度。
主要发现
- 中位起病年龄24岁(范围1-80岁),男女比1:1.29,初始严重度评分中位4分(范围0-22,满分25分)。
- 33%患者有NF2家族史;最常见临床特征为双侧第VIII脑神经神经鞘瘤(NST)87%、脊髓NST 80%、听力丧失65%、脊髓功能障碍50%、颅内脑膜瘤49%、面瘫36%。
- 研究期间6.1%患者残疾评分进展≥5分。
- 多因素logistic回归显示进展的独立危险因素包括起病年龄<25岁(P=0.015)、家族史阳性(P=0.007)、治疗史阳性(P=0.026)、听力丧失(P=0.014)、面瘫(P=0.015)、失明(P=0.011)、偏瘫(P=0.025)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the clinical features of patients with neurofibromatosis type 2 (NF2) and determine prognostic risk factors for progressive disabilities. METHODS: In this retrospective cohort study of the Japanese national NF2 registry between 2009 and 2013, clinical data (demographic, history, oncologic, and neurologic) of 807 patients with a diagnosis of NF2 were analyzed. The overall severity of neurologic disability was assessed using a comprehensive 25-point scoring system encompassing a wide variety of neurologic deficits. In 587 patients in whom longitudinal disability data were available, multivariate logistic regression was performed to identify risk factors for significant progression of disability. RESULTS: The clinical characteristics of the Japanese NF2 population were heterogeneous. The median age of onset was 24 years (range, 1-80 years), the male:female ratio was 1:1.29, and the initial severity score was 4 (range, 0-22) out of 25 points. A family history of NF2 was present in 33% of the patients. Most frequent clinical features were bilateral cranial nerve VIII nerve sheath tumor (NST) in 87%, spinal NST in 80%, hearing loss in 65%, spinal dysfunction in 50%, intracranial meningioma in 49%, and facial paresis in 36%. The disability score progressed by ≥5 points in 6.1% of patients over the study period. Based on multivariate logistic regression analyses, the significant independent risk factors of progression (P value) included age of onset <25 years (P = 0.015), positive family history (P = 0.007), positive treatment history (P = 0.026), hearing loss (P = 0.014), facial paresis (P = 0.015), blindness (P = 0.011), and hemiparesis (P = 0.025). CONCLUSIONS: The Japanese NF2 population has heterogeneous clinical features. Risk factors for progressive disability include younger age of onset, positive family history, positive treatment history, and specific neurologic deficits.
引用
- Iwatate K, Yokoo T, Iwatate E, et al. Population Characteristics and Progressive Disability in Neurofibromatosis Type 2. World Neurosurg. 2017. PMID: 28720529. doi:10.1016/j.wneu.2017.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。